Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

Louis P. Garrison, Deborah Lubeck, Deepa Lalla, Virginia Paton, Amylou Dueck, Edith A. Perez

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials. METHODS. A Markov model with 4 health states was used to estimate the cost utility for a 50-year-old woman on the basis of trial results through 4 years and estimates of long-term recurrence and death based on a meta-analysis of trials. From 6 years onward, rates of recurrence and death were assumed to be the same in both trastuzumab and chemotherapy-only arms. Incremental costs were estimated for diagnostic and treatment-related costs. Analyses were from payer and societal perspectives, and these analyses were projected to lifetime and 20-year horizons. RESULTS. Over a lifetime, the projected cost of trastuzumab per quality-adjusted life year (QALY; discount rate 3%) gained was $26,417 (range, $9104-$69,340 under multiway sensitivity analysis). Discounted incremental lifetime cost was $44,923, and projected life expectancy was 3 years longer for patients who received trastuzumab (19.4 years vs 16.4 years). During a 20-year horizon, the projected cost of adding trastuzumab to chemotherapy was $34,201 per QALY gained. Key cost-effectiveness drivers were discount rate, trastuzumab price, and probability of metastasis. The cost-effectiveness result was robust to sensitivity analysis. CONCLUSIONS. Trastuzumab for adjuvant treatment of early stage breast cancer was projected to be cost effective over a lifetime horizon, achieving a cost-effectiveness ratio below that of many widely accepted oncology treatments.

Original languageEnglish (US)
Pages (from-to)489-498
Number of pages10
JournalCancer
Volume110
Issue number3
DOIs
StatePublished - Aug 1 2007

Fingerprint

Cost-Benefit Analysis
Breast Neoplasms
Costs and Cost Analysis
Quality-Adjusted Life Years
Therapeutics
Adjuvant Chemotherapy
Recurrence
Drug Therapy
Trastuzumab
human ERBB2 protein
Life Expectancy
Health Care Costs
Meta-Analysis
Economics
Neoplasm Metastasis
Mortality
Health

Keywords

  • Adjuvant
  • Cost effectiveness
  • Cost utility
  • Early breast cancer
  • Economics
  • HER2
  • Herceptin
  • Pharmacoeconomics
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. / Garrison, Louis P.; Lubeck, Deborah; Lalla, Deepa; Paton, Virginia; Dueck, Amylou; Perez, Edith A.

In: Cancer, Vol. 110, No. 3, 01.08.2007, p. 489-498.

Research output: Contribution to journalArticle

Garrison, Louis P. ; Lubeck, Deborah ; Lalla, Deepa ; Paton, Virginia ; Dueck, Amylou ; Perez, Edith A. / Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. In: Cancer. 2007 ; Vol. 110, No. 3. pp. 489-498.
@article{72a451a8f03d4cfc8f6fd780d5689a2c,
title = "Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer",
abstract = "BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials. METHODS. A Markov model with 4 health states was used to estimate the cost utility for a 50-year-old woman on the basis of trial results through 4 years and estimates of long-term recurrence and death based on a meta-analysis of trials. From 6 years onward, rates of recurrence and death were assumed to be the same in both trastuzumab and chemotherapy-only arms. Incremental costs were estimated for diagnostic and treatment-related costs. Analyses were from payer and societal perspectives, and these analyses were projected to lifetime and 20-year horizons. RESULTS. Over a lifetime, the projected cost of trastuzumab per quality-adjusted life year (QALY; discount rate 3{\%}) gained was $26,417 (range, $9104-$69,340 under multiway sensitivity analysis). Discounted incremental lifetime cost was $44,923, and projected life expectancy was 3 years longer for patients who received trastuzumab (19.4 years vs 16.4 years). During a 20-year horizon, the projected cost of adding trastuzumab to chemotherapy was $34,201 per QALY gained. Key cost-effectiveness drivers were discount rate, trastuzumab price, and probability of metastasis. The cost-effectiveness result was robust to sensitivity analysis. CONCLUSIONS. Trastuzumab for adjuvant treatment of early stage breast cancer was projected to be cost effective over a lifetime horizon, achieving a cost-effectiveness ratio below that of many widely accepted oncology treatments.",
keywords = "Adjuvant, Cost effectiveness, Cost utility, Early breast cancer, Economics, HER2, Herceptin, Pharmacoeconomics, Trastuzumab",
author = "Garrison, {Louis P.} and Deborah Lubeck and Deepa Lalla and Virginia Paton and Amylou Dueck and Perez, {Edith A.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1002/cncr.22806",
language = "English (US)",
volume = "110",
pages = "489--498",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

AU - Garrison, Louis P.

AU - Lubeck, Deborah

AU - Lalla, Deepa

AU - Paton, Virginia

AU - Dueck, Amylou

AU - Perez, Edith A.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials. METHODS. A Markov model with 4 health states was used to estimate the cost utility for a 50-year-old woman on the basis of trial results through 4 years and estimates of long-term recurrence and death based on a meta-analysis of trials. From 6 years onward, rates of recurrence and death were assumed to be the same in both trastuzumab and chemotherapy-only arms. Incremental costs were estimated for diagnostic and treatment-related costs. Analyses were from payer and societal perspectives, and these analyses were projected to lifetime and 20-year horizons. RESULTS. Over a lifetime, the projected cost of trastuzumab per quality-adjusted life year (QALY; discount rate 3%) gained was $26,417 (range, $9104-$69,340 under multiway sensitivity analysis). Discounted incremental lifetime cost was $44,923, and projected life expectancy was 3 years longer for patients who received trastuzumab (19.4 years vs 16.4 years). During a 20-year horizon, the projected cost of adding trastuzumab to chemotherapy was $34,201 per QALY gained. Key cost-effectiveness drivers were discount rate, trastuzumab price, and probability of metastasis. The cost-effectiveness result was robust to sensitivity analysis. CONCLUSIONS. Trastuzumab for adjuvant treatment of early stage breast cancer was projected to be cost effective over a lifetime horizon, achieving a cost-effectiveness ratio below that of many widely accepted oncology treatments.

AB - BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials. METHODS. A Markov model with 4 health states was used to estimate the cost utility for a 50-year-old woman on the basis of trial results through 4 years and estimates of long-term recurrence and death based on a meta-analysis of trials. From 6 years onward, rates of recurrence and death were assumed to be the same in both trastuzumab and chemotherapy-only arms. Incremental costs were estimated for diagnostic and treatment-related costs. Analyses were from payer and societal perspectives, and these analyses were projected to lifetime and 20-year horizons. RESULTS. Over a lifetime, the projected cost of trastuzumab per quality-adjusted life year (QALY; discount rate 3%) gained was $26,417 (range, $9104-$69,340 under multiway sensitivity analysis). Discounted incremental lifetime cost was $44,923, and projected life expectancy was 3 years longer for patients who received trastuzumab (19.4 years vs 16.4 years). During a 20-year horizon, the projected cost of adding trastuzumab to chemotherapy was $34,201 per QALY gained. Key cost-effectiveness drivers were discount rate, trastuzumab price, and probability of metastasis. The cost-effectiveness result was robust to sensitivity analysis. CONCLUSIONS. Trastuzumab for adjuvant treatment of early stage breast cancer was projected to be cost effective over a lifetime horizon, achieving a cost-effectiveness ratio below that of many widely accepted oncology treatments.

KW - Adjuvant

KW - Cost effectiveness

KW - Cost utility

KW - Early breast cancer

KW - Economics

KW - HER2

KW - Herceptin

KW - Pharmacoeconomics

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=34547095237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547095237&partnerID=8YFLogxK

U2 - 10.1002/cncr.22806

DO - 10.1002/cncr.22806

M3 - Article

C2 - 17592827

AN - SCOPUS:34547095237

VL - 110

SP - 489

EP - 498

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -